Baseline and toxicity characteristics overall and by age
| Overall N (%) | <65 years N (%) | 65–74 years N (%) | ≥75 years N (%) | X2 | ||||||
| No of patients (%) | 448 (100) | 185 (41.3) | 154 (34.4) | 109 (24.3) | ||||||
| Median age (range) | 67 (21–96) | 55 (21–64) | 70 (65–74) | 79 (75–96) | ||||||
| Primary site (%) | ||||||||||
| Melanoma | 258 (57.6) | 109 (58.9) | 74 (48.1) | 75 (68.8) | ||||||
| Lung | 116 (25.9) | 36 (19.5) | 58 (37.7) | 22 (20.2) | ||||||
| Renal | 74 (16.5) | 40 (21.6) | 22 (14.3) | 12 (11.0) | ||||||
| First-line treatment (%) | ||||||||||
| Pembrolizumab | 287 (64.1) | 99 (53.5) | 102 (66.2) | 86 (78.9) | ||||||
| Nivolumab | 87 (19.4) | 47 (25.4) | 25 (16.2) | 15 (13.8) | ||||||
| Ipilimumab+nivolumab | 54 (12.1) | 28 (15.1) | 23 (14.9) | 3 (2.8) | ||||||
| Ipilimumab | 20 (4.5) | 11 (6.0) | 4 (2.6) | 5 (4.6) | ||||||
| Median no of cycles (range) | 6 (1–60) | 5 (1–60) | 7 (1–49) | 7 (1–33) | ||||||
| All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | All grade | ≥G3 | |
| All toxicity | 270 (60.3) | 72 (16.1) | 111 (60.0) | 35 (18.9) | 97 (63.0) | 25 (16.2) | 62 (56.9) | 12 (11.0) | NS | NS |
| Adverse event | ||||||||||
| Dermatitis | 100 (22.3) | 4 (0.9) | 35 (18.9) | 0 (0.0) | 34 (22.1) | 2 (1.3) | 31 (28.4) | 2 (1.8) | NS | NS |
| Lower GI | 88 (19.6) | 27 (6.0) | 37 (20.0) | 15 (8.1) | 32 (20.8) | 7 (4.6) | 19 (17.4) | 5 (4.6) | NS | NS |
| Endocrine | 88 (19.6) | 11 (2.5) | 42 (22.7) | 4 (2.2) | 34 (22.1) | 5 (3.3) | 12 (11.0) | 2 (1.8) | 0.02 | NS |
| Hepatitis | 56 (12.5) | 16 (3.6) | 30 (16.2) | 6 (3.2) | 16 (10.4) | 6 (3.9) | 10 (9.2) | 4 (3.7) | NS | NS |
| Rheumatological | 25 (5.6) | 4 (0.9) | 7 (3.8) | 2 (1.1) | 10 (6.5) | 2 (1.3) | 8 (7.3) | 0 (0.0) | NS | NA |
| Other | 77 (17.2) | 18 (4.0) | 32 (17.3) | 9 (4.9) | 31 (20.1) | 7 (4.6) | 14 (12.8) | 2 (1.8) | NS | NS |
| Overall N (%) (n=302) | <65 years N (%) (n=112) | 65–74 years N (%) (n=109) | ≥75 years N (%) (n=81) | X2 | ||||||
| Discontinuation due to toxicity | 40 (13.2) | 23 (20.5) | 11 (10.1) | 6 (7.4) | 0.006 | |||||
A total of 448 patients overall for which toxicity data are known, 302 patients for which continuation/discontinuation data are known.
GI, gastrointestinal; NA, Insufficient patient numbers for analysis; NS, not significant.